logo

Biotech Daily Dose

Share

pharma-072817_16jan20.jpg Today's Daily Dose brings you news about the FDA panel's split verdict on DURECT's postoperative nonopioid pain relief depot, BioNTech's acquisition of Neon Therapeutics and the FDA designating Envafolimab as an orphan drug for the treatment of biliary tract cancer.

pharma-062717_15jan20.jpg Today's Daily Dose brings you news about Kala Pharma's completion of enrollment in STRIDE 3 trial, Rockwell Medical's license and supply agreements with India-based Sun Pharmaceutical and upcoming regulatory catalyst of DURECT.

pharma-070717_09jan20.jpg Today's Daily Dose brings you news about Applied Genetic's X-linked retinitis pigmentosa trial results, FDA approval of the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors and DBV Tech's long-term data from phase III open-label extension study of Viaskin Peanut, among others.

pharma-062117_08jan20.jpg Today's Daily Dose brings you news about Applied Therapeutics' ACTION-Galactosemia trial results, FDA approval of Merck's Keytruda for yet another indication, Verastem's a global licensing agreement with Chugai Pharma and SCYNEXIS' FURI study results.

pharma-060217_07jan20.jpg Today's Daily Dose brings you news about Apellis Pharma's PEGASUS study results; Advaxis' progress with ADXS-504 in prostate cancer; CEL-SCI Corp's stock offering and Tyme's strategic collaboration with Eagle Pharma.

pharma-061317_06jan20.jpg Today's Daily Dose brings you news about Xeris Pharma's trial results of ready-to-use (RTU) glucagon for the prevention of exercise-induced hypoglycemia; Merck's Keytruda trial results in patients with extensive-stage small-cell lung cancer; collaboration and license agreement between aTyr Pharma and Kyorin Pharmaceutical.

pharma-062017_02jan20.jpg Today's Daily Dose brings you news about Agile Therapeutics' strengthened commercial leadership team; DURECT's decision to discontinue the development of DUR-928 in mild to moderate plaque psoriasis; Novan's disappointing molluscum contagiosum trial results; Incyte's acute graft-versus-host disease trial results and Innate Pharma's regulatory catalyst that drove the stock to a new 52-week high.

europeanstock1-dec16_31dec19.jpg Shares of BioXcel Therapeutics Inc. (BTAI) closed Tuesday, the last trading day of 2019, at $14.61, up a whopping 338% in the year.

eyegate-dec31.jpg Shares of EyeGate Pharmaceuticals Inc. (EYEG), which closed at a new 52-week high of $12.20 on Monday, have gained an impressive 312% in the last three months.

erytech-dec31.jpg French biotech ERYTECH Pharma S.A. (ERYP) has gained nearly 40% this month as the Company progresses with its lead product candidate Eryaspase, which is based on its proprietary ERYCAPS platform.

pharma-061917_30dec19.jpg Today's Daily Dose brings you news about Aridis Pharma's collaboration with privately-held Mapp Biopharmaceutical; FDA approval for AZN/MRK's Lynparza for yet another indication; Axsome Therapeutics' continuing momentum; Sol-Gel's acne trial results; update on X4 Pharmaceuticals' Mavorixafor, and jail term for the Chinese scientist He Jiankui.

cassava-dec30.jpg Shares of Cassava Sciences Inc. (SAVA), which closed at a 52-week high of $5.21 on Friday (Dec.27), are up a whopping 210% over the last 6 trading days.

avenuetherapeutics-dec30.jpg Shares of Avenue Therapeutics Inc. (ATXI), which closed at an all-time high of $9.22, have gained 56% so far this month.

Mereo BioPharma Group plc (MREO) has gained over 160% in the last three trading days as it gears up for a couple of important clinical trial catalysts in the coming year.

Iterum Therapeutics plc (ITRM) has two clinical trial catalysts to watch out for in the first quarter of 2020.

Follow RTT
>